title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Study oversight | The study was designed by the authors in conjunction with the sponsor and conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation Guidelines for Good Clinical Practice. The study protocol and amendments were approved by the institutional review boards a... | PMC10504075 | ||
Treatment | toxicity | DISEASE PROGRESSION | All patients received subcutaneous elranatamab 76 mg QW on a 28-d cycle with a two step-up priming dose regimen of 12 mg on day 1 and 32 mg on day 4 during the first week, with the exception of the first four patients enrolled in the study who received a single priming dose of 44 mg on day 1 before receiving the full d... | PMC10504075 |
Efficacy and safety assessments | CRS | The primary endpoint was confirmed ORR, defined as PR or better (≥PR) according to IMWG criteriaAEs were graded according to the NCI CTCAE (version 5.0), except for CRS and ICANS, which were graded according to the criteria of the American Society for Transplantation and Cellular TherapyAll analyses were performed in t... | PMC10504075 | |
Statistical analysis | CRS | SECONDARY, EMD | Efficacy and safety were evaluated in all patients enrolled who received at least one dose of elranatamab (safety analysis set). A sample size of 120 patients was estimated to give a power of at least 98% to establish an ORR of more than 30% at a one-sided significance level of 0.025, assuming an ORR of at least 48%. A... | PMC10504075 |
Reporting summary | Further information on research design is available in the | PMC10504075 | ||
Online content | Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41591-023-02528-9. | PMC10504075 | ||
Supplementary information |
Supplementary Tables 1 and 2.Reporting Summary | PMC10504075 | ||
Extended data | PMC10504075 | |||
Extended data | is available for this paper at 10.1038/s41591-023-02528-9. | PMC10504075 | ||
Supplementary information | The online version contains supplementary material available at 10.1038/s41591-023-02528-9. | PMC10504075 | ||
Acknowledgements | This study was funded by Pfizer. The authors would like to thank the patients who participated in the trial and the medical staff of participating centers. The medical writing support was provided by G. Shay-Lowell, Ph.D., CMPP, of Engage Scientific Solutions and was funded by Pfizer. | PMC10504075 | ||
Author contributions | All authors were involved in the trial conception/design, or the acquisition, analysis, or interpretation of data. All authors contributed to the drafting of the manuscript and approved the final version. | PMC10504075 | ||
Peer review | PMC10504075 | |||
Data availability | Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified patient data. See | PMC10504075 | ||
Competing interests | ONCOLOGY | A.M.L. reports consulting or advisory roles for Pfizer, Trillium Therapeutics and Arcellx; personal fees from ITeos Therapeutics, Janssen, Legend Biotech, Pfizer, Sanofi and Trillium Therapeutics; institutional research support from Bristol-Myers Squibb, Genentech, Janssen Oncology, Pfizer, Sanofi, Trillium Therapeutic... | PMC10504075 | |
References | PMC10504075 | |||
Background | coronavirus disease 2019 | CORONAVIRUS DISEASE 2019 | In a randomized trial, Lianhuaqingwen (LHQW) capsule was effective for accelerating symptom recovery among patients with coronavirus disease 2019 (COVID-19). However, the lack of blinding and limited sample sizes decreased the level of clinical evidence. | PMC10685492 |
Objectives | To evaluate the efficacy and safety of LHQW capsule in adults with mild-to-moderate COVID-19. | PMC10685492 | ||
Methods | We conducted a double-blind randomized controlled trial in adults with mild-to-moderate COVID-19 (17 sites from China, Thailand, Philippine and Vietnam). Patients received standard-of-care alone or plus LHQW capsules (4 capsules, thrice daily) for 14 days. The primary endpoint was the median time to sustained clinical ... | PMC10685492 | ||
Results | sore throat, myalgia, cough, tiredness, headache, shivering, chills, shortness of breath | SORE THROAT, ADVERSE EVENTS | The full-analysis set consisted of 410 patients in LHQW capsules and 405 in placebo group. LHQW significantly shortened the primary endpoint in the full-analysis set (4.0 vs. 6.7 days, hazards ratio: 1.63, 95% confidence interval: 1.39-1.90). LHQW capsules shortened the median time to sustained clinical improvement or ... | PMC10685492 |
Supplementary Information | The online version contains supplementary material available at 10.1186/s12985-023-02144-6. | PMC10685492 | ||
Keywords | PMC10685492 | |||
Introduction | coronavirus disease 2019 | CORONAVIRUS, CRITICAL ILLNESS, SEVERE ACUTE RESPIRATORY SYNDROME, CORONAVIRUS DISEASE 2019 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the culprit of coronavirus disease 2019 (COVID-19), is continuously evolving globally [Several therapeutic approaches have been developed to reduce the symptom burden and the probability of progression into severe or critical illness. These mainly include an... | PMC10685492 |
Methods | PMC10685492 | |||
Study design and patients | The FLOSAN trial recruited patients with mild-to-moderate COVID-19 from 12 hospitals in China, 3 hospitals in Thailand, and one hospital each in Vietnam and the Philippines between February and December 2022 (Additional file Baseline demographic and clinical characteristics of the full-analysis set | PMC10685492 | ||
Randomization and masking | RECRUITMENT | We randomly assigned patients (1:1) to receive treatment with LHQW or matching placebo (manufactured by Shijiazhuang Yiling Pharmaceutical Co. Ltd., Shijiazhuang, China) based on the randomization numbers generated with the SAS package (SAS Inc., Cary, USA). The block size was 4 with no stratification. With competitive... | PMC10685492 | |
Procedures | fever | RECRUITMENT | After randomization, patients took LHQW (4 capsules [0.35g/capsule], thrice daily) or matching placebo for 14 consecutive days following hospitalization in designated hospitals (in mainland China) and out-patient recruitment (in the Phillipines, Thailand and Viet Nam). Both groups received standard-of-care consisting o... | PMC10685492 |
Outcomes | gastrointestinal symptoms, COVID-19-related severe/critical disease, ground-glass opacity, ageusia, anosmia | SECONDARY, INFILTRATION, ADVERSE EVENT | The primary endpoint was evaluated at day 14 - the median time to sustained clinical improvement or resolution of the nine above-mentioned major symptoms, rated as being less than or equal to mild (scored 1 or 0) and remained stable for >24 hours (see Supplementary File for the symptom diary cards).Pre-specified second... | PMC10685492 |
Statistical analysis | anosmia, death, ageusia, fever | EVENTS, RECRUITMENT, DISEASES, VIRAL SHEDDING | Assuming that the median time to sustained improvement or resolution was 12 days in control group and 9 days in LHQW group, 652 patients would be randomized to LHQW or placebo group (1:1) with a 95% power with a two-sided significance of 0.05 according to PASS software. In practice, patients were enrolled while taking ... | PMC10685492 |
Role of funding source | The sponsor participated in the study design along with the principal investigators, study medication provision and data collection. An independent third party participated in data analysis. The first and corresponding authors had full access to the data and the corresponding author had the final decision to submit the... | PMC10685492 | ||
Discussion | DISEASE, CRITICAL ILLNESS | The FLOSAN study is the first international multicenter randomized controlled trial that evaluates the safety and efficacy of LHQW capsules among patients with mild-to-moderate COVID-19 in the western Pacific region. Treatment with LHQW for 14 days significantly shortened the time to sustained improvement or resolution... | PMC10685492 | |
Conclusion | LHQW capsules are effective and safe for mild-to-moderate COVID-19 via accelerating symptom resolution and clinical recovery for mild-to-moderate COVID-19. LHQW might be worthwhile for patients who could now be managed within the community. | PMC10685492 | ||
Acknowledgements | RECRUITMENT, INFECTIOUS DISEASE | We thank Jihan Huang, PhD. (Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine) for performing the independent statistical analysis. We thank Shijiazhuang Yiling Pharmaceutical Co., Ltd. (Shijiazhuang, People’s Republic of China) for provision of the study medications. We also thank ... | PMC10685492 | |
Author contributions | P. | J. P. Z., Z. F. Y. and N. S. Z. participated in study design; Y. L., L. S. J., P. M., H. Z. L., M. C., L. X. Z., P. A., F. Y. H., T. T. N. L., R. A. P., X. G., H. M. S., J. J. J., R. J. L., Z. D. and Y. Q. Z. recruited patients and performed follow up; W. J. G., J. P. Z. and N. S. Z. drafted the manuscript; J. P. Z. an... | PMC10685492 | |
Funding | The study was funded by Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine [No: ZYYCXTD-D-202206], and the Science and Technology Program of Hebei 225A2503D. | PMC10685492 | ||
Availability of data and materials | Data could be shared after publication after consultation with the corresponding authors. | PMC10685492 | ||
Declarations | PMC10685492 | |||
Ethics approval and consent to participate | Ethics approval has been obtained the ethics committee of each participating site, based on | PMC10685492 | ||
Competing interests | None. | PMC10685492 | ||
References | PMC10685492 | |||
Key Points | PMC10690456 | |||
Question | What are the cardiometabolic effects of a healthy plant-based (vegan) vs a healthy omnivorous diet among identical twins during an 8-week intervention? | PMC10690456 | ||
Findings | weight loss | In this randomized clinical trial of 22 healthy, adult, identical twin pairs, those consuming a healthy vegan diet showed significantly improved low-density lipoprotein cholesterol concentration, fasting insulin level, and weight loss compared with twins consuming a healthy omnivorous diet. | PMC10690456 | |
Meaning | The findings from this trial suggest that a healthy plant-based diet offers a significant protective cardiometabolic advantage compared with a healthy omnivorous diet.This randomized clinical trial of identical twin pairs compares the cardiometabolic effects of a healthy vegan diet with a healthy omnivorous diet. | PMC10690456 | ||
Importance | Increasing evidence suggests that, compared with an omnivorous diet, a vegan diet confers potential cardiovascular benefits from improved diet quality (ie, higher consumption of vegetables, legumes, fruits, whole grains, nuts, and seeds). | PMC10690456 | ||
Objective | To compare the effects of a healthy vegan vs healthy omnivorous diet on cardiometabolic measures during an 8-week intervention. | PMC10690456 | ||
Design, Setting, and Participants | MAY | This single-center, population-based randomized clinical trial of 22 pairs of twins (N = 44) randomized participants to a vegan or omnivorous diet (1 twin per diet). Participant enrollment began March 28, 2022, and continued through May 5, 2022. The date of final follow-up data collection was July 20, 2022. This 8-week... | PMC10690456 | |
Intervention | Twin pairs were randomized to follow a healthy vegan diet or a healthy omnivorous diet for 8 weeks. Diet-specific meals were provided via a meal delivery service from baseline through week 4, and from weeks 5 to 8 participants prepared their own diet-appropriate meals and snacks. | PMC10690456 | ||
Main Outcomes and Measures | The primary outcome was difference in low-density lipoprotein cholesterol concentration from baseline to end point (week 8). Secondary outcome measures were changes in cardiometabolic factors (plasma lipids, glucose, and insulin levels and serum trimethylamine | PMC10690456 | ||
Results | A total of 22 pairs (N = 44) of twins (34 [77.3%] female; mean [SD] age, 39.6 [12.7] years; mean [SD] body mass index, 25.9 [4.7]) were enrolled in the study. After 8 weeks, compared with twins randomized to an omnivorous diet, the twins randomized to the vegan diet experienced significant mean (SD) decreases in low-de... | PMC10690456 | ||
Conclusions and Relevance | In this randomized clinical trial of the cardiometabolic effects of omnivorous vs vegan diets in identical twins, the healthy vegan diet led to improved cardiometabolic outcomes compared with a healthy omnivorous diet. Clinicians can consider this dietary approach as a healthy alternative for their patients. | PMC10690456 | ||
Trial Registration | ClinicalTrials.gov Identifier: | PMC10690456 | ||
Introduction | Plant-based diets have gained recent popularity not only for their lower environmental impact compared with an omnivorous dietary pattern but also for their health benefits.A vegan dietary pattern is typically lower in energy density but higher in fiber, vitamins, minerals, and phytonutrients compared with other dietar... | PMC10690456 | ||
Methods | This study followed the ethical standards of the Declaration of Helsinki | PMC10690456 | ||
Study Design | MAY | This single-site, parallel-group, dietary intervention randomized clinical trial randomized healthy, adult identical twins to a healthy vegan or omnivorous diet for 8 weeks. Participant enrollment began March 28, 2022, and continued through May 5, 2022. The date of final follow-up data collection was July 20, 2022.The ... | PMC10690456 | |
Participants | We aimed to recruit 22 pairs of identical twins 18 years or older, a sample size determined by resource availability rather than a formal power calculation. Identical twins were recruited primarily from the Stanford Twin Registry and randomized using computerized random-number generation by a statistician (K.M.C.) blin... | PMC10690456 | ||
Dietary Intervention | The study consisted of two 4-week phases: delivered meals and self-provided meals. Participants were provided all no-cost meals for the first 4 study weeks by a nationwide meal delivery company (Trifecta Nutrition). It was expected that after 4 weeks of food delivery and health educator counseling that participants wou... | PMC10690456 | ||
Collection of Dietary Intake | SECONDARY | Two types of dietary data were collected. For the primary reporting data, 3 unannounced 24-hour dietary recalls—a structured interview intended to capture detailed information about food and drink intakes—were administered within a 1-week window (2 weekdays and 1 weekend day) of each time point (baseline, week 4, and w... | PMC10690456 | |
Anthropometric and Metabolic Data | BLOOD | At 3 time points, participants visited the Stanford Clinical and Translational Research Unit after an overnight fast of 10 to 12 hours: baseline, 4 weeks (phase 1), and 8 weeks (phase 2). Blood draw and clinical measures were assessed using standard methods (eMethods in | PMC10690456 | |
Statistical Analysis | Descriptive statistics, mean (SD) or number (percentage), were used for continuous and categorical variables, respectively. | PMC10690456 | ||
Baseline Characteristics of the Study Participants | Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.SI conversion factors: To convert HDL-C and LDL-C to mmol/L, multiply by 0.0259; triglycerides to mmol/L, multiply by 0.011... | PMC10690456 | ||
Results | A total of 22 pairs of randomized twins (N = 44) were enrolled in the study. The CONSORT flow diagram of participants ( | PMC10690456 | ||
TwiNS CONSORT Flow Diagram | PMC10690456 | |||
Cardiovascular Health Outcomes at the End of 8 Weeks and Main Effect Model Estimates for Primary and Secondary Outcome Analyses | SECONDARY | Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TMAO, trimethylamine SI conversion factors: To convert HDL-C and LDL-C to mmol/L, multiply by 0.0259; triglycerides to mmol/L, multiply by 0.0113; glucose to mmol/L, multiply by 0.0555; insulin to pmol/L, multiply by... | PMC10690456 | |
Diet and Nutrient Intake | Reported energy intake during each of the two 4-week phases (food delivery and self-provided) were lower compared with baseline for both groups (eFigures 1 to 5 and eTables 2 to 6 and 23 in | PMC10690456 | ||
Primary Outcome | Participants receiving the vegan diet showed a mean (SD) decrease of 13.9 (5.8) mg/dL (95% CI, −25.3 to −2.4 mg/dL) in the unadjusted mean LDL-C level at 8 weeks from baseline compared with participants receiving the omnivorous diet ( | PMC10690456 | ||
Median Change From Baseline to 8 Weeks in Primary and Secondary Outcomes Between Vegan and Omnivorous Diet Arms | SECONDARY | For primary and secondary outcomes, percent change and | PMC10690456 | |
Secondary Outcomes | Compared with participants receiving the omnivorous diet, participants receiving the vegan diet saw a significant mean (SD) decrease of 2.9 (1.3) μIU/mL in fasting insulin (95% CI, −5.3 to −0.4 μIU/mL) from baseline to 8 weeks ( | PMC10690456 | ||
Sensitivity Analysis | Three outlier TMAO levels greater than 15 μM were noted: 2 at baseline and 1 at 8 weeks. After the outliers were eliminated, the TMAO level was significantly different between diet groups at 8 weeks: in this analysis, participants on the vegan diet showed a mean (SD) decrease of −2.1 (0.7) μM (95% CI, −3.5 to −0.7 μM) ... | PMC10690456 | ||
Exploratory Analysis | Paired and unpaired 2-tailed | PMC10690456 | ||
Discussion | eating a vegan diet | In this randomized clinical trial of healthy, adult identical twins, the 8-week change in LDL-C level—the primary outcome—was significantly lower for twins receiving the vegan diet compared with twins receiving the omnivorous diet. Insulin levels and weight were also significantly lower among the twins on the vegan die... | PMC10690456 | |
Strengths and Limitations | Several aspects of our design and implementation were strengths. First, enrolling identical twins was beneficial because we were able to eliminate the confounding influences of age, sex, and genetic factors that may affect clinical outcomes. Identical twins often share a similar environment and lifestyle, reducing envi... | PMC10690456 | ||
Conclusions | cardiometabolic | In this randomized clinical trial, we observed cardiometabolic advantages for the healthy vegan vs the healthy omnivorous diet among healthy, adult identical twins. Clinicians may consider recommending plant-based diets to reduce cardiometabolic risk factors, as well as aligning with environmental benefits. | PMC10690456 | |
Abstract | PMC9939110 | |||
Introduction | lung cancer, SCLC | LUNG CANCER, SCLC | Currently, only a few options are available for the treatment of patients with small‐cell lung cancer (SCLC) after the failure of first‐line platinum‐based chemotherapy. The present study aimed to evaluate the efficacy and safety of apatinib plus chemotherapy for second‐line treatment of advanced SCLC. | PMC9939110 |
Patients and Methods | toxicity | DISEASE, DISEASE PROGRESSION, SECONDARY | This prospective clinical trial recruited patients treated with apatinib plus second‐line chemotherapy until disease progression or intolerable toxicity. Logrank test power analysis was used for calculating samples. The primary endpoint was progression‐free survival (PFS), and the secondary endpoints were objective res... | PMC9939110 |
Results | thrombocytopenia, proteinuria, neutropenia, leucopenia | ADVERSE EVENTS, THROMBOCYTOPENIA, NEUTROPENIA, LEUCOPENIA | A total of 29/31 enrolled patients were available for response evaluation until October 2019. The ORR and DCR were 27.59% (8/29) and 96.55% (28/29), respectively. The median PFS and OS were 7.36 months and 14.16 months, respectively, indicating better efficacy compared with the standard second‐line chemotherapies. The ... | PMC9939110 |
Conclusion | SCLC, toxicities | SCLC | Antiangiogenic therapy plus chemotherapy had encouraging efficacy in advanced SCLC patients, which provides an insight into the current status of second‐line therapy in SCLC.Antiangiogenic therapy (Apatinib) plus chemotherapy had better efficacy compared with standard second‐line chemotherapies for advanced SCLC patien... | PMC9939110 |
INTRODUCTION | toxicity, SCLC, Lung cancer | LUNG CANCER, SCLC, EVENT | Lung cancer regarded as one of the most common causes of cancer‐related mortality.Apatinib is an oral tyrosine kinase inhibitor (TKI) that specifically inhibits the vascular endothelial growth factor receptor‐2 (VEGFR‐2). As a new antiangiogenic drug, apatinib has shown promising clinical efficacy for SCLC patients. Da... | PMC9939110 |
PATIENTS AND METHODS | PMC9939110 | |||
Patients | SCLC, allergic | BRAIN METASTASIS, SCLC, MALIGNANT TUMORS, ONCOLOGY, DISEASE PROGRESSION | In this single‐arm, phase II prospective study, pretreated patients with advanced SCLC were selected. The eligibility criteria were as follows: (1) 18–75‐years‐old; (2) Eastern Cooperative Oncology Group (ECOG) performance score ≤2; (3) Pathological examination confirmed SCLC; (4) Limited stage patients could receive t... | PMC9939110 |
Treatment schedule | death | DISEASE PROGRESSION, ADVERSE EFFECT | Initially, 18 patients were administered 500 mg apatinib once per day plus four cycles of chemotherapy, followed by single apatinib (500 mg) treatment until disease progression, death, intolerance, or consent withdrawal. Because of the intolerance to the dosage regimen at the primary stage, 13 patients were subsequentl... | PMC9939110 |
Efficacy and toxicity evaluation | death, Tumor, toxicity, Tumors, Toxicity, Cancer | TUMORS, DISEASE PROGRESSION, TUMOR, CANCER | All the patients were followed up until disease progression or death. Tumor response was evaluated by imaging every two cycles of treatment (every 6 weeks) according to the Response Evaluation Criteria in Solid Tumors guidelines version 1.1 (RECIST1.1). Any toxicity was observed and graded according to the National Can... | PMC9939110 |
Study endpoints | death | DISEASE, DISEASE PROGRESSION, SECONDARY | The primary endpoint of this study was PFS (the time from the start of treatment to the time of disease progression or death). The secondary endpoints included objective response rate (ORR) (proportion of patients achieving complete response or partial response), disease control rate (DCR) (proportion of patients with ... | PMC9939110 |
Statistical analysis | SCLC | SCLC | Previous large‐scale clinical studies indicated that the longest PFS of second‐line single‐agent chemotherapy for SCLC lasted about 4 months (Table | PMC9939110 |
RESULTS | PMC9939110 | |||
Patient characteristics | ONCOLOGY, MAY | A total of 31 patients were enrolled in this study from May 31, 2018 to October 25, 2019. The baseline characteristics of the subjects are listed in Table Clinical baseline characteristics of total patients (Abbreviations: ECOG, Eastern Cooperative Oncology Group. | PMC9939110 | |
Treatment outcomes | The detailed treatment outcomes of the 31 patients were depicted in the swimmers plot (Figure.Clinical outcomes and survival analysis of the patients. (A) Swimmers plot of survival outcomes of 31 patients. (B) Waterfall plot of best response among the evaluable 29 patients. Kaplan–Meier plots of (C) PFS and (D) OS.Subg... | PMC9939110 | ||
Treatment duration of apatinib and OS | DISEASE PROGRESSION | In the current study, the median treatment duration of apatinib was 7.36 months, and the median duration of single apatinib maintenance therapy was 4.93 months. In the cohort, 15 patients used apatinib for less than 6 months, and 16 patients used it for more than 6 months. The difference in OS between the two groups of... | PMC9939110 | |
Subsequent therapy and OS | DISEASE PROGRESSION | Next, 22/31 patients discontinued treatment due to disease progression. Among them, 15 patients accepted subsequent chemotherapy, and seven patients did not accept any subsequent anti‐cancer therapies. In this study, we observed that patients who accepted subsequent chemotherapy had longer OS than those who refused the... | PMC9939110 | |
Multiple metastases and survival | BRAIN METASTASIS, METASTASIS, BONE METASTASIS, LYMPH NODE METASTASIS, LIVER METASTASIS | Organ metastasis analyses revealed that 9/31 (29.03%) patients had brain metastasis, but no significant clinical symptoms, 4/21 (12.9%) patients had liver metastasis, 12/31 (38.71%) patients had lymph node metastasis, 5/31 (16.13%) had adrenal metastasis, and 2/31 (6.45%) had bone metastasis (Table | PMC9939110 | |
Safety | neutropenia, diarrhea, thrombocytopenia, proteinuria, leucopenia, deaths, hypertension, hand‐foot syndrome | NEUTROPENIA, ADVERSE EVENTS, ADVERSE EVENT, THROMBOCYTOPENIA, LEUCOPENIA, HYPERTENSION | The most common adverse events (AEs) were neutropenia (41.94%, 13/31), followed by leucopenia (35.48%, 11/31), and thrombocytopenia (25.81%, 8/31). The other common AEs were proteinuria (22.58%, 7/31), diarrhea (22.58%, 7/31), hypertension (22.58%, 7/31), and hand‐foot syndrome (22.58%, 7/31). Almost all the patients h... | PMC9939110 |
Dose adjustment of apatinib | toxicities, hypertension, neutropenia, diarrhea | HYPERTENSION, NEUTROPENIA | Compared with the patients using 500 mg apatinib as the initial dose, the occurrence of treatment‐related AEs in the subgroup of patients using 250 mg initial apatinib was more optimistic. Consequently, 7/31 (22.58%) cases of intermittent medication, including four patients in the 500 mg dose group and three in the 250... | PMC9939110 |
DISCUSSION | NSCLC, SCLC, vascularized malignant tumors, tumor, toxicity, lung cancer, gastric cancer | COLORECTAL CANCER, TUMOR, SCLC, PROLIFERATION, DISEASE, LUNG CANCER, HEPATOCELLULAR CARCINOMA, NSCLC, GASTRIC CANCER | Over the past two decades, antiangiogenic therapy has gained increasing attention because of its success in resisting multiple vascularized malignant tumors, such as colorectal cancer, NSCLC, and hepatocellular carcinoma.Herein, we used an oral small molecular antiangiogenic TKI apatinib in combination with chemotherap... | PMC9939110 |
CONCLUSION | toxicity, SCLC | SCLC | Antiangiogenic therapy (apatinib) plus chemotherapy had encouraging efficacy. Also, no intolerable toxicity was observed for this new regimen, which should provide an insight into the current status of second‐line therapy in SCLC. | PMC9939110 |
AUTHORS’ CONTRIBUTIONS | Kewei Ma had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Conception and design: Kewei Ma and Yinghui Xu. Acquisition, analysis, or interpretation of data: Xu Wang, Chao Sun, Junya Song. Drafting of the manuscript: Yinghui Xu, Z... | PMC9939110 | ||
FUNDING INFORMATION | ONCOLOGY | K. Ma was supported by Wu Jieping Medical Foundation. Dr Y. Xu was supported by Youth Foundation of Norman Bethune Health Science Center of Jilin University (Grant ID: 2018B28) and Xisike Clinical Oncology Research Foundation (CSCO‐Haosen) (Grant ID: Y‐HS2017062). | PMC9939110 | |
CONFLICT OF INTEREST | The authors declare that they have no conflicts of interest or competing interests. | PMC9939110 | ||
Supporting information |
Figure S1
Figure. S2
Figure. S3
Table S1
Table S2
Table S3
Table S4
Click here for additional data file. | PMC9939110 | ||
ACKNOWLEDGMENT | We would like to thank all the patients and their families for their important contribution in the whole process of this study. This study was funded by Jiangsu Hengrui Pharmaceuticals. We would also like to acknowledge Y. Yu and X. Su statistical analysis (funded by Hengrui). | PMC9939110 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.